Replies to post #3827 on Insmed Inc (INSM)

[gismo]

Please read this from Isnmed PR. They are just talking about the servere short stature.

The lawsuit centers around Iplex (rhIGF-I/rhIGFBP-3), Insmed's IGF-1 therapy, approved by the FDA to treat children with severe short stature.

http://biz.yahoo.com/bw/061206/20061206006008.html?.v=1

[Do DD]

If I remember correctly Avecia manufactures iPlex in the EU on behalf of INSM. Therefore production and consumption of iPlex will most probably take place in the EU. Therefore no influence of American patents on EU situation.
However, there has been a summary judgment decision over the EU '417 patent, which is somewhat comparable to the '515 in the US.
However claim construction differed materially from the current claim construction in the US.

E.